Product Description
ABBV-2222 (formerly GLPG2222) is a type of CFTR modulator called a corrector. (Sourced from: )
Mechanisms of Action: CFTR Modulator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Galapagos
Company Location: 2800 MECHELEN C9 00000
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Cystic Fibrosis
Phase 1: Cystic Fibrosis|Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| 2006-7041-83/hah | N/A |
Not yet recruiting |
Other |
2024-02-01 |
|||
| 2006-7041-83/hah | N/A |
Not yet recruiting |
Anterior Cruciate Ligament Injuries |
2022-09-01 |
|||
| M23-492 FE | P1 |
Completed |
Cystic Fibrosis |
2022-12-21 |
23% |
2023-01-12 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
| ABBV-576 DDI | P1 |
Completed |
Cystic Fibrosis |
2022-11-29 |
12% |
2023-02-24 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
| FALCON | P1 |
Completed |
Cystic Fibrosis |
2019-03-11 |
3% |
2019-04-09 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
| GLPG2222-CL-101 | P1 |
Completed |
Healthy Volunteers |
2016-04-01 |
2019-03-20 |
||
| M19-771 | P2 |
Terminated |
Cystic Fibrosis |
2023-06-05 |
69% |
2023-06-24 |
Primary Endpoints |
| 2018-000098-61 | P2 |
Terminated |
Cystic Fibrosis |
2018-07-13 |
2022-03-13 |
Treatments |
|
| GLPG2222-CL-202 | P2 |
Completed |
Cystic Fibrosis |
2017-10-19 |
2019-03-21 |
Treatments |
|
| 2016-004477-40 | P2 |
Completed |
Cystic Fibrosis |
2017-10-19 |
2022-03-13 |
Treatments |
|
| 2016-002837-31 | P2 |
Completed |
Cystic Fibrosis |
2017-08-24 |
2022-03-13 |
Treatments |
|
| GLPG2222-CL-201 | P2 |
Completed |
Cystic Fibrosis |
2017-08-11 |
2019-03-21 |
Treatments |
|
| 2020-005805-25 | P2 |
Completed |
Cystic Fibrosis |
None |
69% |
2025-07-07 |
Treatments |